---
aliases: []
---
#actor #biotech #bci #neurotech #usa #private

**Neuralink** — Brain-computer interface. $9B valuation. 12 human implants. FDA breakthrough designation. Thought-to-text trials.

---

## Why Neuralink matters

| Metric | Value |
|--------|-------|
| Founded | 2016 |
| Founder | [[Elon Musk]] |
| Valuation | **$9B** (2025) |
| Total raised | $1.2B+ |
| Human implants | **12** (as of Sep 2025) |
| FDA status | **Breakthrough designation** |

---

## Funding history

| Round | Amount | Valuation |
|-------|--------|-----------|
| Pre-2023 | ~$600M | — |
| 2023 | — | $5B |
| 2025 | **$600M** | **$9B** (+80%) |

**Investors:** Founders Fund, ARK Invest, Sequoia, [[Valor Equity Partners]], G42, Thrive Capital.

---

## Clinical trials

| Milestone | Date |
|-----------|------|
| FDA IDE approval | May 2023 |
| First human implant | Jan 2024 |
| 12 patients implanted | Sep 2025 |
| Canada expansion | Aug-Sep 2025 |
| UK first patient | Oct 2025 |
| Thought-to-text trial | Oct 2025 (FDA approved) |

**Usage:** 2,000+ cumulative days, 15,000+ hours across patients.

---

## Technology

| Component | Detail |
|-----------|--------|
| Device | N1 implant |
| Electrodes | 1,024 channels |
| Threads | Ultra-thin (thinner than hair) |
| Surgery | Robotic implantation (R1 robot) |
| Power | Wireless charging |
| Interface | Bluetooth to devices |

---

## Applications

| Use case | Status |
|----------|--------|
| Paralysis (cursor control) | In trials |
| Thought-to-text | Trial starting |
| Spinal cord injury | Testing |
| Vision restoration | Future |
| Memory enhancement | Future |

---

## Challenges

| Issue | Detail |
|-------|--------|
| Thread retraction | 85% detached in first patient |
| Brain shift | 3x more than expected |
| Regulatory timeline | Full approval late 2020s |
| Safety concerns | Lithium battery, long-term effects |

---

## Competitive landscape

| Company | Approach |
|---------|----------|
| Neuralink | Invasive, high-bandwidth |
| Synchron | Less invasive (blood vessel) |
| Blackrock Neurotech | Research-focused |
| Paradromics | High-channel count |
| Kernel | Non-invasive |

---

## Investment case

**Bull:**
- FDA breakthrough designation
- 12 successful implants
- Musk resources/visibility
- Massive TAM (neurological conditions)
- $9B valuation reasonable vs potential

**Bear:**
- Private (no public access)
- Early technical challenges (thread retraction)
- Regulatory uncertainty
- Ethical concerns
- Competition from less invasive approaches

---

## Quick stats

| Metric | Value |
|--------|-------|
| Status | Private |
| Valuation | $9B |
| Implants | 12 patients |
| Focus | Brain-computer interface |

---

## Related

- [[Elon Musk]] — founder
- [[Valor Equity Partners]] — investor
- [[Biopharma]] — sector adjacent

---

## Sources

- [Neuralink updates](https://neuralink.com/updates/)
- [Sacra: Neuralink](https://sacra.com/c/neuralink/)
- [MIT Technology Review](https://www.technologyreview.com/2025/01/16/1110017/what-to-expect-from-neuralink-in-2025/)

*Created 2026-01-09*
